Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.
Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study
Foti, C;Di Leo, E;Patruno, C;Macchia, L;Napolitano, M;Romita, P;Di Bona, D;Carbonara, M;
2020-01-01
Abstract
Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
vol32issue2_4.pdf
accesso aperto
Descrizione: articolo principale
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
380.64 kB
Formato
Adobe PDF
|
380.64 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
